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The objective of this study was to determine whether patients beginning therapy on the most common tricyclic
antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) differed in their likelihood ofhaving
antidepressant treatment that was consistent with recommended treatment guidelines in the UK. An analytical
file constructed from a large general practitioner medical records database (DIN-LINK) from the UK for the
years 1992-97 was constructed. A total of 16 204 patients with a new episode of antidepressant therapy who
initiated therapy on one of the most often prescribed TCAs (amitriptyline, dothiepin, imipramine and
lofepramine) or SSRIs (fluoxetine, paroxetine and sertraline) were analysed. A dichotomous measure was
defined to indicate whether subjects were prescribed at least 120 days of antidepressant therapy at an
adequate average daily dose within the first 6 months after initiation of therapy. Only 6.0% of patients
initiating therapy on aTCA and 32.9% of patients initiating therapy on a SSRI were prescribed antidepressant
treatment that was consistent with treatment guidelines. After controlling for observable characteristics,
patients who initiated therapy on a SSRI were much more likely (odds ratio=7.473, p<0.001) to have a
prescribed average daily dose and duration consistent with recommended treatment guidelines within the
first 6 months of initiating therapy than were patients who initiated therapy on a TCA. These findings suggest
that initial antidepressant selection is an important determinant ofwhether the subsequent course of treatment
is consistent with current national guidelines for the treatment of depression in the UK.
Key words: antidepressants; depression; drug prescribing patterns; selective serotonin reuptake inhibitors;
tricyclic antidepressants
Introduction
Antidepressant dose and duration are two important factors in
achieving the goals of depression treatment which include not
only symptom resolution, but also restoration of patients'
functioning and prevention of relapse or recurrent episodes.
Consensus guidelines have been issued by the British
Association for Psychopharmacology (British Association for
Psychopharmacology, 1993) and the Royal College of
Psychiatrists (Royal College of Psychiatrists, 1992) for the
management of depression with antidepressants. For treat-
ment to be effective, they recommend that antidepressants
should be prescribed at a dose shown by clinical trials to be
effective in treating depression, and continued for at least 4
months beyond initial symptom resolution. These guidelines
are broadly consistent with other consensus groups' recom-
mendations (World Health Organization Mental Health
Collaborating Centres, 1989; Agency for Health Care Policy
Research, 1993).
Most clinical trials of different antidepressants generally
show equal efficacy (Effective Health Care Bulletin, 1993;
Anderson and Thomenson, 1994; Song et al., 1994). However,
studies of antidepressant use in clinical practice ('naturalistic'
studies) have shown that most patients who initiate therapy on
a tricyclic antidepressant (TCA) in primary care in the UK
begin at suboptimal doses and remain there (Donoghue and
Tylee, 1996; Donoghue et al., 1996; Martin et al., 1997). In
addition, studies have also shown that most patients beginning
treatment with a TCA are less likely than patients on selective
serotonin reuptake inhibitors (SSRIs) to refill their prescrip-
tions and often discontinue therapy by the third month
(MacDonald, 1997).
Naturalistic, observational studies of antidepressant use in
clinical practice can complement the findings from controlled
trials. A feature of observational studies is that the results are
more generalizable to broader populations than those consid-
ered in controlled clinical trials due to the lack of study
conditions or protocol restrictions. However, unlike rando-
mized controlled clinical trials, observational studies are subject
to the influence of confounding factors. Previous observational
studies of antidepressant prescribing patterns in primary care in
the UK have been limited by their cross-sectional design
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(Donoghue, 1995, 1996; Donoghue and Tylee, 1996;
Donoghue et al., 1996). In addition, the only naturalistic,
longitudinal study of antidepressant prescribing patterns in the
UK to date did not address the influence of other observed
patient or prescriber characteristics on prescribing patterns
(MacDonald, 1997). Thus, it was unclear whether the
differences in observed prescribing patterns were due to the
drugs or to other factors that influence both drug selection and
prescribing.
The purpose of this study was to assess how the prescribing
patterns of different antidepressants in the first 6 months
following initiation of treatment compare with recommended
depression treatment guidelines in the UK. We considered a
sample of patients in primary care who had a depression-
related diagnosis at the initiation of therapy. All patients in
this study initiated therapy on one of the most commonly
prescribed TCAs (amitriptyline, dothiepin, imipramine and
lofepramine) or SSRIs (fluoxetine, paroxetine and sertraline),
which represented over 97% of all antidepressant prescribing
in primary care in this study. Unlike earlier studies, this one
considers a longer period of prescribing data (1992-97),
constructs and analyses patients' episodes of antidepressant
use, and uses logistic regression analysis to control for the
influence of other observed factors.
Methods
Data
The analysis file used in this study was constructed from the
1992-97 panels of the Doctors' Independent Network (DIN-
LINK), which is maintained by CompuFile Ltd. (Woking,
UK). DIN-LINK is a system of comprehensive and standar-
dized medical and prescription records for approximately
750 000 patients from 100 general practices in the UK that use
AAH Meditel practice software. A 6-month antidepressant-
free period prior to the index date was used to ensure that
antidepressant prescribing was not part of an earlier episode.
Episodes of antidepressant therapy were then constructed
using an intent-to-treat basis. In an intent-to-treat design,
patients' subsequent experience in the study period is
attributed back to the original TCA or SSRI selected,
regardless of subsequent use. For example, if a patient begins
on a TCA and then switches to a SSRI or another
antidepressant, the patient remains in the TCA category for
the analysis. An intent-to-treat analysis is consistent with
examining the consequences of initial antidepressant selection
(Simon et al., 1996).
The 'index study' antidepressant was one of the four study
TCAs or three SSRIs on which the patient began therapy. The
index date was defined as the date on which the first
prescription for the study antidepressant was issued and was
accompanied by one of five depression-related diagnoses (as
recorded in the medical record, including endogenous depres-
sion, reactive depression, depressed, on examination depressed
or depression not otherwise specified) within a 30-day period
around the index date. These diagnoses are consistent with
those used and validated in earlier analyses of the DIN-LINK
data (Donoghue, 1996; Donoghue and Tylee, 1996). General
practitioners use all of these terms to describe depression in
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primary care in the UK, and do not use them consistently to
differentiate between different manifestations of depression.
Patients were excluded if they: (I) were unable to be
followed for at least 180 days before the index date; (2) did not
have 180 days of continuous health care coverage in the same
general practitioner practice after the index date; (3) were
prescribed more than one index study antidepressant at the
index date; (4) had antidepressant use in the 180-day prior
period; (5) had multiple records of the study antidepressant on
the index date; or (6) were less than 18 years of age at the index
date. After the exclusions, the analytical file included 16 204
patients representing 99 general practices.
Statistical analysis
A logistic regression model was used to determine the effect of
drug class on antidepressant prescribing patterns. The
dependent variable was defined as a dichotomous variable
indicating whether or not the patient was prescribed anti-
depressant prescriptions at recommended average daily doses
for an adequate duration.
Challenges in defining patterns of antidepressant prescribing
with retrospective data are well-known (Simon et al., 1993;
Fairman, 1997). Even with dates of prescriptions, it is not
possible to know exactly when patients finished the contents of
one prescription or started on another. Patients may take
additional daily doses, miss doses during therapy, or refill
prescriptions other than the day the supply of the previous
prescription has been exhausted. Any measure of prescribing
outcomes will involve compromises given the nature of the
data. Adequate duration was met if the combined expected
duration of all prescriptions was at least 120 days of the first
180 days beginning with initiation of therapy. This definition
allowed for no more than one 30-day gap between anti-
depressant prescriptions in the first 6 months. Recommended
daily dosages used were 20 mg for paroxetine, fluoxetine, and
citalopram, 50mg for sertraline, 75mg for venlafaxine, 100mg
for nefazadone, 125mg for amitriptyline, amoxapine, clomi-
pramine, desipramine, dothiepin, doxepin, imipramine, and
maprotiline and 140mg for lofepramine. Thus, at least 120
days of antidepressant therapy at recommended daily doses
within the first 6 months after initiation of therapy was
considered to be a reasonable estimation of treatment
consistent with guidelines in the UK.
The main explanatory variable was a binary indicator of
SSRI use, with TCAs, the most common antidepressants, as
the reference group. Controlling for other factors in the
regression, this variable enables a comparison of the odds of
receiving adequate treatment for patients initiating therapy on
an SSRI relative to patients initiating therapy on a TCA.
Other factors besides drug selection may also influence the
prescribing patterns and were included in the analysis as
additional explanatory variables. These factors include patient
demographics (age and sex) and region of the country. Other
variables included were related to the patient's comorbid
conditions at the index date or in the prior period. First, four
binary indicators for depression diagnosis at the index date
were created (i.e. endogenous depression, reactive depression,
depressed and on examination depressed, with depression not
otherwise specified as the reference group). Second., binary
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indicator variables were created for the following conditions if
they occurred in the 180-day period prior to initiation of
therapy: cancer, chronic fatigue syndrome, coronary artery
disease, stroke, diabetes and fibromyalgia. These are condi-
tions commonly coexisting with depression (AHCPR, 1993).
Third, several variables were created which represented counts
of the following occurrences in the 180-day prior period:
anxiolytic prescriptions, sedative-hypnotics prescriptions, gen-
eral practitioner visits, general practitioner referrals,
psychotherapy referrals, laboratory referrals, psychiatric acci-
dent and emergency admissions, psychiatric non-accident and
emergency admissions, general accident and emergency
admissions and general non-accident and emergency admis-
sions. Fourth, in an attempt to control for concomitant
psychiatric conditions, indicators were created for Psychiatric
Diagnostic Groups (Ashcraft et al., 1989) which are based on
the ICD-9 classification scheme. Psychiatric Diagnostic
Groups were defined as a method of classifying major
psychiatric conditions and are therefore analogous to the
Major Diagnostic Categories used in the Diagnosis Related
Groups classification system.
Finally, an additional variable was included to reduce the
effect of factors related to the general practice characteristics
such as habitual antidepressant prescribing practices. This
variable represents the probability that the general practi-
tioners at the patient's general practice prescribed SSRIs and
was measured by computing the percentage of the general
practice's study antidepressant prescriptions which were for
SSRIs during the study period. Physicians' practice patterns
may be shaped by a number of influences, including previous
experience with the product and the information physicians
receive about the product and its use. Thus, unlike previous
studies of antidepressant prescribing, it was possible to control
for underlying differences in general practices that are likely to
prescribe TCAs or SSRIs. In this way, differences in
physicians' habitual prescribing practices, preferences or
previous experiences with different classes of drugs are
controlled for (Simon and Fishman, 1998).
A standard significance level (p<0.05) was used for the
analysis. The SAS package (SAS Institute, Cary, North
Carolina, USA) was used to construct the dataset and perform
the logistic regression analysis.
Results
Table I presents descriptive results of the variables used in the
analysis. Of the 16 204 patients in the sample, 62.0%
(n= 10054) initiated therapy on one of the most often
prescribed TCAs (amitriptyline, dothiepin, imipramine and
lofepramine) while approximately 38.0% (n=6150) initiated
therapy on one of the most often prescribed SSRIs (fluoxetine,
paroxetine and sertraline). Before adjusting for other potential
confounding variables, SSRI patients (32.9%) were much
more likely than TCA patients (6.0%) to be prescribed at least
120 days of antidepressant therapy at the recommended
average daily dosage in the first 6 months after starting
therapy. The main reason for SSRI patients not achieving
adequate use was fewer than 120 days of therapy within the
first 6 months. The main reason for TCA patients not
achieving adequate use was average daily doses below the
recommended values for one or more prescriptions. Notably,
only 9.0% of the TCA treated patients experienced upward
dose titration.
The unadjusted odds ratio of having an adequate dose and
duration of antidepressant was 7.68. After controlling for
other observable variables through logistic regression analysis,
the results showed that the odds of having an adequate dose
and duration of antidepressant therapy was still over sevenfold
higher for patients taking a SSRI than for TCA patients (odds
ratio = 7.473, p<0.001, Table 2). By including the other
variables related to patients' demographics and comorbid
conditions, these factors were controlled for in the analysis.
Although a number of these other variables were statistically
significant individually, the adjusted odds ratio (7.47) and the
unadjusted odds ratio (7.68) were similar.
These results were not sensitive to alternative specifications
of the model and different definitions of an adequate
prescribing pattern. An additional analysis was performed
using 75mg as a minimum average daily dose for the TCAs
(except lofepramine). In this case, 15.6% of patients who
started on a TCA were found to have an adequate dose and
duration, compared with 34.1% of patients who started on a
SSRI. For this analysis, the multiple regression results
indicated that the odds of having an adequate dose and
duration were nearly threefold higher for SSRI patients
compared with TCA patients (odds ratio=2.825,p<0.00l).
Analysis of lotepramine patients (n = 2076) separately
indicated that lofepramine patients achieve adequate dose
and duration 18.3% of the time, compared with 2.8% for
patients on the other TCAs. Removing lofepramine subjects
from the logistic regression resulted in an odds ratio of 17.063
(p <0.001) for the comparison of SSRIs with the older TCAs,
compared with an odds ratio of 7.473 when the lofepramine
patients were included with the other TCA patients. Analysis
of SSRI patients relative to lofepramine patients only resulted
in an odds ratio of 2.236 (p<0.001).
Discussion
How antidepressants are prescribed in clinical practice could
differ due to differences in convenience, tolerability, and a
variety of complex interactions between patient, prescriber and
health care service characteristics. Meta-analyses of controlled
trials of antidepressants (Anderson and Tomenson, 1994;
Montgomery et al., 1994) have found differences in drop-out
rates due to side-effects with lower rates for SSRIs relative to
TCAs. The SSRIs are also less toxic in overdose (Henry et al.,
1995). Recent analyses have also found a perception among
general practitioners of differences in tolerability between the
TCAs and SSRIs (Martin et al., 1997). In addition, it is
acknowledged that lofepramine does appear to be used
differently in clinical practice owing to (at least perceived)
differences in tolerability (Donoghue and Tylee, 1996). Thus,
there is some evidence that antidepressant prescribing in
clinical practice may be driven, in part, by the perception of
tolerability differences across TCAs and SSRIs.
In this study, overall rates of prescribing of TCA and SSRI
antidepressants in relation to treatment guidelines were low.
0010024
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Table I Descriptive statistics by index study antidepressant class
Selective serotonin reuptake inhibitor Tricyclic antidepressant patients
patients (n = 6150) (n = 10 054)
n % n 0 p-values*
Adequate Dose and Duration 0.001
Yes 2022 32.90 604 6.0%
No -recommended dose but not 3701 60.2 ,o 1324 13.2,,
recommended duration
No-recommended duration but not 135 2.2(Mo 2454 24.4%
recommended dose
No-not recommended dose or 292 4.7% 5672 56.4%
duration
Index Depression Diagnosis 0.001
Depression not otherwise specified 2967 48.2% 4816 47.9%
Endogenous depression 1506 24.5% 2395 23.8%
Reactive depression 797 13.0% 1576 15.7%
Depressed 753 12.2% 1124 11.2%
On examination- depressed 127 2.1% 143 1.4%
Location 0.001
Southern England 3026 49.2 o/ 4411 43.9%o
Northern England and Scotland 2648 43.1'0o 5041 50.1%o
Wales 476 7.7% 602 6.0%
Sex 0.001
Male 1647 26.8% 2345 23.3%
Female 4503 73.2% 7709 76.7%
Mean SD Mean SD
Age 45.224 17.631 48.576 17.933 <0.001
Counts of medical occurrences in the 180 day prior period
Anxiolytic prescriptions 0.107 0.748 0.119 0.853 0.598
Sedative-hypnotics prescriptions 0.247 1.286 0.273 1.282 0.557
General practitioner visits 6.840 6.076 6.691 5.782 0.432
General practitioner referrals 1.041 2.470 0.954 2.295 0.011
Psychotherapy referrals 0.094 0.570 0.068 0.535 <0.001
Laboratory referrals 0.078 0.726 0.103 0.757 0.004
Psychiatric accident and emergency admissions 0.010 0.136 0.005 0.096 <0.001
Psychiatric non-accident and emergency 0.005 0.137 0.001 0.028 0.001
admissions
General accident and emergency admissions 0.058 0.492 0.050 0.394 0.223
General non-accident and emergency 0.136 0.721 0.119 0.637 0.255
cldmissions
Indicator of Psychiatric Diagnostic Group occurrence in the 180 day prior period
Organic mental disorders and 0.009 0.096 0.007 0.081 0.065
alcohol use disorders
Opioid and other substance use disorders 0.005 0.067 0.005 0.068 0.912
Schizophrenic disorders 0.002 0.046 0.001 0.030 0.041
Other psychotic disorders 0.001 0.025 0.001 0.026 0.914
Bipolar disorders 0.001 0.031 0.001 0.030 0.870
Major depressions 0.160 0.367 0.147 0.354 0.023
Other specific and atypical affective disorders 0.001 0.031 0.001 0.036 0.567
Post-trauumatic stress disorders 0.005 0.067 0.004 0.067 0.943
Anxiety disorders 0.045 0.207 0.041 0.198 0.245
Personality disorders 0.001 0.025 0.002 0.040 0.098
Impulse control, adjustment disorders, other 0.039 0.194 0.038 0.192 0.840
mental
Indicator of other medical conditions in the 180 day prior period
Chronic fatigue syndrome 0.003 0.054 0.004 0.063 0.277
Cancer 0.013 0.111 0.014 0.117 0.482
Coronary artery disease 0.051 0.219 0.043 0.204 0.030
Stroke 0.016 0.127 0.014 0.117 0.202
Diabetes 0.021 0.144 0.023 0.150 0.510
Fibromyalgia 0.005 0.073 0.006 0.080 0.423
General Practice Drug Class Preference
Frequency of general practice selective 0.444 0.170 0.323 0.144 <0.001
serotonin reuptake inhibitor prescriptions
*p-values for use patterns, index depression diagnosis, location, and sex are based on chi-squared tests of independence. The p-value for age is based
on an unequal variance t-test. All other p-values are based on the non-parametric Wilcoxon rank-sum test.
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Table 2 Odds ratios (confidence intervals) and p-values from a logistic regression model predicting the log odds of having received 120 days oftherapy on the study antidepressant in the first 6 months following initiation of therapy at an adequate dosage
Variable Odds ratio p-value
Drug type chosen
Indicator of selective serotonin reuptake inhibitor as study 7.473 (6.752-8.272) <0.001
antidepressant class
Demographics
Age at index date 1.004 (1.001-1.007) 0.005
Female indicator 0.918 (0.828-1.019) 0.108
Location
Wales indicator 0.708 (0.580-0.864) 0.001
Southern England indicator 1.023 (0.931-1.123) 0.641
Index Depression Diagnosis
Endogenous depression 1.192 (1.069-1.329) 0.002
Reactive depression 0.855 (0.737-0.991) 0.037
Depressed 0.737 (0.632-0.861) <0.001
On examination depressed 0.718 (0.502-1.027) 0.070
Counts of medical occurrences in the 180 day prior period
Anxiolytic prescriptions 1.005 (0.951-1.062) 0.866
Sedative-hypnotics prescriptions 1.025 (0.989-1.063) 0.174
General practitioner visits 1.014 (1.005-1.024) 0.003
General practitioner referrals 0.989 (0.969-1.010) 0.313
Psychotherapy referrals 1.052 (0.977-1.134) 0.181
Laboratory referrals 0.953 (0.883-1.028) 0.209
Psychiatric accident and emergency admissions 1.066 (0.761-1.494) 0.708
Psychiatric non-accident and emergency admissions 0.927 (0.571-1.504) 0.759
General accident and emergency admissions 1.044 (0.954-1.143) 0.352
General non-accident and emergency admissions 1.036 (0.973-1.104) 0.273
Indicator of Psychiatric Diagnostic Group occurrence in the 180 day prior period
Organic mental disorders and alcohol use disorders 1.167 (0.733-1.856) 0.516
Opioid and other substance use disorders 0.521 (0.240-1.130) 0.099
Schizophrenic disorders 0.675 (0.215-2.120) 0.501
Other psychotic disorders 0.892 (0.169-4.701) 0.893
Bipolar disorder 0.568 (0.111-2.895) 0.496
Major depressions 1.342 (1.187-1.516) <0.001
Other specific and atypical affective disorders 2.936 (0.989-8.717) 0.053
Post-traumatic stress disorders 0.902 (0.453-1.796) 0.770
Anxiety disorders 1.112 (0.896-1.379) 0.336
Personality disorders 2.892 (0.923-9.057) 0.068
Impulse control, adjustment disorders, other mental 0.992 (0.780-1.262) 0.948
Indicator of other medical conditions in the 180 day prior period
Chronic fatigue syndrome 0.652 (0.276-1.536) 0.328
Cancer 0.983 (0.665-1.454) 0.932
Coronary artery disease 1.010 (0.816-1.250) 0.927
Stroke 0.963 (0.675-1.375) 0.835
Diabetes 0.972 (0.717-1.318) 0.857
Fibromyalgia 0.716 (0.379-1.352) 0.303
General Practice Drug Class Preference
Frequency of general practice selective serotonin 2.259 (1.669-3.058) <0.001
reuptake inhibitor prescriptions
However, patients who initiated therapy on a SSRI had an
odds ratio over sevenfold higher than patients who initiated
therapy on a TCA of having an adequate daily dose and
duration of antidepressant therapy consistent with recom-
mended treatment guidelines. In light of the absolute
differences between the classes of antidepressants (6% for
TCA patients and 32.9% for SSRI patients), this difference is
also clinically relevant, particularly when it is considered over
a large population.
The large sample size and the similarity of findings of
previous studies of antidepressant prescribing using these data
with other databases in the UK (Donoghue and Tylee, 1996)
contributes to the generalizability of these data to the UK as a
whole. Consistent with earlier cross-sectional studies
(Donoghue and Tylee, 1996; Donoghue et al., 1996; Martin
et al., 1997), patients who initiated therapy on SSRIs were
more likely to achieve recommended therapeutic doses than
their counterparts on TCAs in primary care in the UK. The
results were also qualitatively consistent with the earlier
longitudinal study in Scotland (MacDonald, 1997). In that
study, only 1% of TCA patients had an adequate dose and
duration compared with 29% of SSRI patients.
In a recent randomized, prospective trial in the Group
Health Cooperative Health Maintenance Organization in the
USA, patients randomized to desipramine, imipramine or
fluoxetine were equally likely to continue on any antidepres-
sant for at least 90 days at an adequate dose (Simon et al.,
1996). While that finding contrasts with the results of this
study, it may be that the physicians who participated in that
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observed in clinical practice in terms of their experience in
participating in trials and how they manage patients on
antidepressants. Patients referred to that trial may also have
been systematically different than patients in the general
population. This possibility is consistent with the finding of a
similar retrospective (non-clinical trial) study of a broader
sample of physicians and patients in the Group Health
Cooperative setting which found that the likelihood of
continuing antidepressant on any medication was statistically
significantly higher for patients who had initiated therapy on
the SSRI fluoxetine than patients who had initiated therapy on
a TCA (Katon et al., 1992).
The relatively low rates of adequate daily dose and duration
for patients initiating therapy on any antidepressant are
striking in light of the recent Defeat Depression campaign in
the period 1991-96 in the UK (Priest, 1994). For the 1992-94
period of the sample, 5.3% of TCA patients had an adequate
dose and duration of therapy vs 7.9% of TCA patients in
1995-97, while the figures for SSRI subjects were 29.4% in
1992-94 and 37.8% in 1995-97. An earlier cross-sectional
analysis of prescriptions in the DIN-LINK data found that the
rate of adequate dose of antidepressant prescribing had
increased during 1993-95, due largely to increased prescribing
of the SSRIs (Donoghue et at., 1996). It would appear that
efforts to increase awareness of appropriate treatment
strategies with antidepressants have increased the likelihood
of achieving adequate daily dose and duration, regardless of
which antidepressant they were prescribed. Even in light of this
educational awareness program, it would appear that this
likelihood is still greater with an SSRI relative to a TCA.
The observed prescribing patterns of TCAs and SSRIs in
clinical practice may also have implications for cost-effective-
ness comparisons that rely upon controlled clinical trial data.
Recent analyses have concluded that because TCAs and SSRIs
are generally equally efficacious, TCAs represent a more cost-
effective solution because of the acquisition price differential
(Effective Health Care Bulletin, 1993; Song et al., 1994;
Hotopf et at., 1996). This conclusion might have credence if
TCAs were used in actual clinical practice in the same way they
are used in clinical trials (i.e. at adequate doses for sufficient
duration). However, the findings of this and other studies
indicate they are not. Rather, patients on TCAs begin at low
doses and remain there.
This study's results were found despite the fact that the
study design included aspects that favoured the TCAs. First,
using an intent-to-treat design allows the results from patients
who switched antidepressant class to be attributed to the
patient's initial drug class. This favours TCAs because more
patients who initiated therapy on TCAs switched to SSRIs
than vice versa, and SSRI patients were more likely to achieve
adequate daily dose and duration. Second, including lofepra-
mine in the TCA category leads to a higher rate of TCA
patients achieving an adequate dose and duration. While
lofepramine is a TCA. it is generally thought to have lower
toxicity, and thus may be better tolerated, and was found to
have a different pattern of prescribing relative to ainitriptyline
and dothiepin (Donoghue and Tylee, 1996; Donoghue et al.,
1996). The lower odds ratio for SSRI patients relative to
lofepramine patients may only reflect the greater similarity in
the use of SSRIs and lofepramine.
Despite the recommended treatment guidelines in the UK,
some have recently argued that lower doses of TCAs are
appropriate (Benkert et al., 1996; Moore, 1997; Tan, 1997). A
recent meta-analysis of controlled clinical trials also concluded
that there is no difference in efficacy rates between the SSRIs
and TCAs, irrespective of dosing levels (Canadian
Coordinating Office of Health Care Technology, 1998).
However, that meta-analysis only considered acute-phase
trials (4-12 weeks) and it was not clear in that study what
dosage levels of TCAs were considered and in what popula-
tions. Thus, it was not possible to draw conclusions regarding
the long-term efficacy of TCAs at lower doses for the vast
majority of patients who take antidepressants. Achieving all
the goals of antidepressant therapy (symptom resolution,
restoration of patient functioning and relapse prevention)
necessitates considering a long-term perspective beyond acute
phase efficacy and treatment. Thus, until more information
becomes available regarding the long-term safety and efficacy
of low dose TCAs in a controlled clinical trial setting, patients
who initiate therapy on SSRIs may maximize the opportunity
to receive adequate treatment consistent with guidelines
relative to their counterparts on TCAs (Farmer, 1997).
Given the non-randomization into initial antidepressant, it
is possible that differences in antidepressant prescribing
patterns among patients initiating therapy on one of the
antidepressants were the result of unobserved differences
across patients or general practitioners that were not
controlled for in the analysis. For example, it might be that
some patients on the SSRIs differed from TCA patients in
underlying severity, which was not captured by the observed
variables. However, given the information available in this
database and the study design and methods applied, the bias
due to unobserved factors is unlikely to be large. For example,
to control for baseline patient differences, a 6-month prior
period, an extensive set of observable baseline characteristics,
and measures of general practices' experience with the study
antidepressants were used to control for as many of the
baseline patient and physician characteristics as possible. In
addition, comorbid disease variables were included to control
for observed differences across the patient groups in disease
severity. Thus, the observed difference between drug classes is
statistically significant even after controlling for these other
observed factors.
A recent study (Simon and Fishman, 1998) also found that
physicians' habitual prescribing preferences were a stronger
determinant of initial antidepressant drug selection than
patient characteristics. There is also other evidence indicating
that some general practitioners prescribe the same antidepres-
sant for most patients rather than considering specific patient
characteristics when selecting the antidepressant (Matthews et
al., 1993). To this end, a variable measuring the frequency of
the general practice's prescribing of the SSRIs was included in
the DIN-LINK analysis to control for differences in general
practices' characteristics, preferences and prior experience with
the antidepressants, as was a statistically significant determi-
nant in this study. This variable had not been considered in
earlier observational studies of antidepressant use in the UK
and was a new variable to bring to this type of analysis.
It is possible that some patients in the study sample did not
meet the clinical criteria for major depressive disorder and that
189-758
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some patients who were receiving their antidepressant for
major depressive disorders were excluded. Variables measuring
the type of depression diagnosis on the patients' records were
also included to help control for differences in depression
severity. Finally, it was not possible to know whether patients
were taking their medications. It may be that compliance was
worse for TCA patients than SSRI patients if tolerability was a
concern for TCA patients. In addition, low dose TCAs may
have been used as a hypnotic with some patients, even though
a diagnosis of depression was recorded in the database.
However, for this to be a significant factor in these results, this
effect would have to be large, which is unlikely.
Direct measures of clinical outcomes were not available in
these data. Thus, it was not possible to know for certain
whether patients who had a dose and duration of anti-
depressant therapy consistent with guidelines had a greater
clinical improvement relative to other patients. However, some
evidence exists that demonstrates a link between the pattern of
antidepressant prescribing and patient outcome. For example,
one study found that 4 months of antidepressant therapy
increased measures of work restoration fourfold relative to
Imonth of therapy (Mintz et al., 1992) while another study
found that doubling the rate of adequate daily dose and
duration led to a significant reduction in major disabilities
(Sturm and Wells, 1995). An adequate length of stable
antidepressant therapy at an effective dose is also an important
determinant of the prevention of relapse (Maj et al., 1992).
Additional studies are needed to more directly assess the
relationship between treatment consistent with guidelines and
clinical outcomes.
It was not possible to identify the reasons for the observed
dose and duration of therapy. Potential reasons underlying
discontinuation prior to receiving at least 120 days of therapy
within the first 6 months may include lack of clinical effect,
intolerable adverse events, or spontaneous symptom resolu-
tion. It is not possible to determine whether the observed
pattern and lengths of therapy were related to clinical
symptom resolution or to poor patient or prescriber under-
standing of the need to continue treatment for a longer period
of time. Patients who had shorter prescribing patterns may
have been less severely ill and the decision may have been made
to discontinue therapy in light of earlier symptom resolution.
On the other hand, some of the patients who had less than 120
days within the first 6 months may have been more severely ill
but experienced adverse events or lack of efficacy and thus
abandoned treatment altogether.
This study has shown differences in the patterns of
antidepressant prescribing among the most common antide-
pressants in primary care in the UK. It would be useful to
study the relationships between patterns of antidepressant
prescribing, health care expenditures, and clinical outcomes
observed within this primary care setting in the UK. Finally, it
would be useful to consider whether patterns of antidepressant
prescribing differ among the most common SSRIs.
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